Attorney Docket No.: 6196.210-US

USSN: 10/667,040 Filed: September 22, 2003

REMARKS

Entry of this amendment is respectfully requested.

In this amendment, claims 1-4 are cancelled without prejudice and claims 5-12 had been added by a previous amendment. And new claims 13-15 have been added in this amendment. Accordingly, claims 5-15 are pending and at issue.

It is believed that the claims are in condition for allowance, and a determination to that effect is earnestly solicited.

The commissioner is authorized to charge any and all fees in connection with this application, including fees for extensions of time, should such extensions be necessary to the Novo Nordisk® Deposit account. 14-1447 and to credit any overpayments to the same.

Respectfully submitted,

Date: March 8, 2007

Marc A. Began, Reg. No. 48,829 Novo Nordisk Pharmaceuticals, Inc. 100 College Road West Princeton, NJ 08540 (609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE